Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7240 in Moderately to Severely Active Ulcerative Colitis
NCT06052059Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 45
01
Overview
A Phase 3 trial of tulisokibart in ulcerative colitis (UC), sponsored by Merck & Co.. Started Oct 2023; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06052059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052059.